It is suggested that the Holy Grail would be approval of NNZ-2591 for the treatment of Autism, which affects 1% of the globe. I recall hottod commenting to the effect that Neuren was clever in its choice for Phase 2 indications, because success in all 4 could point to success in Autism. With that background, and with the goal of maximizing shareholder value, would it not be most prudent for Neuren to wait for the readout on all 4 phase 2 tests, assuming success in any, and then initiating phase 2 tests for Autism? Instead of selling after success of PMS phase 2 and not knowing what value was left on the table?
It is suggested that the Holy Grail would be approval of...
-
- There are more pages in this discussion • 4,483 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.86 |
Change
0.640(3.17%) |
Mkt cap ! $2.666B | |||
| Open | High | Low | Value | Volume |
| $20.45 | $21.10 | $20.39 | $9.299M | 447.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 671 | $20.85 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.86 | 262 | 1 |
View Market Depth
| Last trade - 16.10pm 26/06/2024 (20 minute delay) ? |
| NEU (ASX) Chart |